Stock comparison
Catalyst Pharmaceuticals
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CPRX
Catalyst Pharmaceuticals
Market cap
$3.83B
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
Overall winner
Catalyst Pharmaceuticals CPRX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CPRX | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 69C | 69B | Tie |
| Benjamin Graham | 75B | 65B | CPRX |
| Philip Fisher | 87C | 63C | CPRX |
| Peter Lynch | 65B | 66B | MTD |
| Joel Greenblatt | 42D | 68B | MTD |
| Charlie Munger | 78B | 74B | CPRX |
| Terry Smith | 78B | 70B | CPRX |
Side-by-side metrics
| Metric | CPRX | MTD |
|---|---|---|
| Market cap | $3.83B | $22.29B |
| P/E (TTM) | 17.3x | 25.3x |
| EV/EBIT | 11.9x | 21.6x |
| ROIC (TTM) | 19.67% | 36.09% |
| Gross margin | 82.32% | 57.79% |
| Net margin | 37.08% | 21.4% |
| Revenue CAGR 5y | 43.0% | 2.01% |
| EPS CAGR 5y | 46.49% | 6.12% |
| Debt / Equity | 0.0x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CPRX leads on
- Revenue CAGR 5y43.0%vs 2.01%+95%
- EPS CAGR 5y46.49%vs 6.12%+87%
- EV/EBIT11.9xvs 21.6x+45%
- Net margin37.08%vs 21.4%+42%
MTD leads on
- Debt / Equity-vs 0.0x+100%
- Market cap$22.29Bvs $3.83B+83%
- ROIC (TTM)36.09%vs 19.67%+45%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.